REG - Oncimmune Hldgs PLC - Grant of Options and PDMR Dealing

Oncimmune HoldingsAnnouncement

04/11/2022 16:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221104:nRSD4292Fa&default-theme=true

RNS Number : 4292F  Oncimmune Holdings PLC  04 November 2022

4 November 2022

 

 

 

Oncimmune Holdings plc

("Oncimmune" or the "Company")

 

Grant of Options and PDMR Dealing

 

Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics
group, today announces that on 3 November 2022, options ("Options") to
subscribe for an aggregate of 196,809 ordinary shares of £0.01 each in the
Company ("Ordinary Shares") were granted to Adam Hill (Chief Executive
Officer), Matthew Hall (Chief Financial Officer) and Ron Kirschner (General
Counsel & Company Secretary) as follows:

 Name           Position                                 No. of Options Awarded  Exercise Price per Share
 Adam Hill      Chief Executive Officer                  125,000                 £0.50
 Matthew Hall   Chief Financial Officer                  30,000                  £0.50
 Ron Kirschner  General Counsel & Company Secretary      30,000                  £0.50

The Options have been granted under the 2016 Share Option Plan, have an
exercise price of £0.50, being the closing price of Ordinary Shares in
Oncimmune Holdings plc on 2 November 2022, and vest annually in five equal
parts from the date of grant until the fifth anniversary of grant.

Following this grant, each of Adam Hill, Matthew Hall and Ron Kirschner hold
the following interests in the Company:

 Name           Number of Ordinary Shares currently held  Number of Options held post grant
 Adam Hill      73,872                                    3,615,862
 Matthew Hall   11,935                                    809,554
 Ron Kirschner  1,652                                     556,738

 

This announcement, including the notification below, is made in accordance
with the requirements of the UK Market Abuse Regulation and serves as
notification and public disclosure of transactions by persons discharging
managerial responsibilities ("PDMR") and persons closely associated with them.

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         1.   Adam Hill

                                                                   2.   Matthew Hall

                                                                   3.   Ron Kirschner
 2    Reason for the notification

 a)   Position/status                                              1.   Chief Executive Officer

                                                                   2.   Chief Financial Officer

                                                                   3.   General Counsel & Company Secretary
 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Oncimmune Holdings plc

 b)   LEI                                                          213800HCYIWT6YPI1I02

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Ordinary Shares of £0.01 each

      Identification code                                          ISIN: GB00BYQ94H38

 b)   Nature of the transaction                                    Grant of options

 c)   Price(s) and volume(s)

                                                                                     Price(s)          Volume(s)
                                                                                     1. £0.50          125,000
                                                                                     2. £0.50          30,000
                                                                                     3. £0.50          30,000

 d)   Aggregated information

      - Aggregated volume                                          N/A - single transaction

      - Price

 e)   Date of the transaction                                      3 November 2022

 f)   Place of the transaction                                     Outside a trading venue

 

 

For further information:

 

Oncimmune Holdings plc

Dr Adam M Hill, Chief Executive Officer

Matthew Hall, Chief Financial Officer

contact@oncimmune.co.uk (mailto:contact@oncimmune.co.uk)

 

Singer Capital Markets (Nominated Adviser and Joint Broker)

Aubrey Powell, Harry Gooden, George Tzimas, James Fischer

+44 (0)20 7496 3000

 

WG Partners (Joint Broker)

David Wilson, Nigel Barnes, Erland Sternby

+44 (0)20 3705 9321

 

 

Media enquiries:

Freelands Finance

John Goold

IR@oncimmune.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHBKQBDABDDNDK